Prognostic Impact of Follistatin in Acute Graft-Versus-Host Disease: Results from BMT CTN 0302 and 0802  by Holtan, Shernan et al.
Figure. Cumulative on acute GVHD by day þ100 in patient who did or did not
receive nTregs.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78S56The median age of Treg-treated patients was 62 (r:45-69), 5
were male, 6 had acute leukemia, 4 had CLL/lymphoma. The
median infused combined nucleated and CD3+ cell doses of
the UCB graft were 4 x10e7 (r:4-9) and 16.5 x 10e6 (r:14-18),
respectively. None had a severe adverse event with the
infusion. One Treg treated patient developed a skin rash on
day +16; biopsy was equivocal for engraftment syndrome to
be conservative we considered as aGVHD. Thus, the inci-
dence of grade 2-4 aGVHD by day +100 was 10% (95% CI, 0-
28%) as compared to 53% (95% CI, 27-79%) in the controls
(p¼.04, Figure). One patient developed grade 3 late gastro-
intestinal aGVHD in the Treg group (day 119). Engraftment
was similar between Treg (90%, 95% CI, 74-99%) and control
(87%, 95% CI, 65-98%) groups (p¼.92). The median follow-up
is too short for assessment of chronic GVHD and relapse. In
summary, we 1) demonstrated the ability to consistently
manufacture Treg doses up to 100 x10 e6/kg which allows
for Treg: T effector ratio of up to 7:1, and 2) observed a
remarkably low risk of aGVHD. This promising result is the
ﬁrst clear demonstration that ex vivo expanded UCB Treg are
potent suppressors of aGVHD in humans and sets the stage
for a future pivotal clinical trial that will assess the clinical
impact of Treg GVHD prophylaxis on immune recovery and
risk of leukemia relapse.39
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Graft versus host disease (GvHD) is the most common
complication of hematopoietic stem cell transplant (HCT).
However, our understanding of the molecular pathways
that cause this disease remains incomplete, leading to
inadequate targeted strategies for prevention and treatment.
To address this, we determined the gene expression proﬁle of
non-human primate (NHP) T cells during active and partially
controlled acute GvHD (aGvHD), in order to accomplish
two goals: 1) uncover important genetic drivers of aGvHDand 2) identify novel, targetable pathways for optimal
aGvHD prevention.
Utilizing microarray technology, we measured the gene
expression proﬁles of ﬂow cytometrically puriﬁed CD3+ T
cells from NHP recipients of MHC partially matched HCT in
three treatment cohorts resulting in increasing degrees of
survival: 1) no immunoprophylaxis (No Rx, MST ¼ 7.5); 2)
sirolimus monotherapy (MST ¼ 17; and 3) tacrolimus-meth-
otrexate (tac-mtx) dual prophylaxis (MST ¼ 49). Arrays were
performed on T cells puriﬁed on Day +14 post-transplant
(unless terminal analysis occurred earlier due to severe dis-
ease). This comparison allowed us to determine the impact of
both mTOR and calcineurin inhibition on the molecular
pathways dysregulated during GvHD, and to determine
which genes and pathways remained dysregulated despite
prophylaxis. Pathways identiﬁed by this strategymay contain
new therapeutic targets unaffected by current immunopro-
phylactic approaches. We found that the transcriptional
proﬁle of donor T cells from HCT recipients with unprophy-
laxed GvHD was characterized by signiﬁcant perturbation of
pathways regulating Tcell proliferation, effector function and
cytokine synthesis. By identifying pathways unaffected by
sirolimus or tac-mtx therapy, we discovered multiple
potentially druggable targets not previously implicated in the
pathophysiology of aGvHD. These targets prominently
included the hedgehog and the aurora kinase A pathways.
Utilizing a murine aGvHD model, we demonstrated that
pharmacologic inhibition of these pathways could mitigate
disease and improve survival.
These data provide the ﬁrst identiﬁcation of the T cell
transcriptome of primate acute GvHD and the hedgehog and
aurora kinase A pathways as novel potential targets for
prevention of this disease.40
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Background: Neovascularization and endothelial dysfunc-
tion are recognized sequelae of acute graft-versus-host
disease (aGVHD). We hypothesized that patients with
abundant angiogenic factors (AF) involved in repair/
regeneration would have improved survival relative to those
with higher levels of AF involved in damage/inﬂammation.
Patients and Methods:Wemeasured circulating levels of AF
known predominantly for repair/regeneration (epidermal
growth factor [EGF], ﬁbroblast growth factor [FGF]-1, FGF-2,
heparin binding-EGF-like growth factor, follistatin [FS],
vascular endothelial growth factor [VEGF]-A, VEGF-C, and
VEGF-D) and those known predominantly for endothelial
dysfunction/inﬂammation (angiopoietin-2 [Ang2], endothe-
lin-1, soluble endoglin [sEng], leptin, placental growth
factor [PlGF]) in HCT recipients with grade III-IV aGVHD
(N¼17) compared to recipients without aGVHD (N¼17) and
healthy stem cell donors (HD, N¼16) in a pilot study. AF
demonstrating <0.5-fold or >1.5-fold difference in median
with p0.1 were validated in two cohorts of patients with
Figure 1. Percent of control levels of 6 angiogenic factors at onset aGVHD in
CTN 0302 and 0802. Data presented are median  SEM.
Figure 2. Kaplan Meier estimate of OS based upon day 28 FS level.
Figure 1. Detection of in vitro activated alloreactive CD4+ T cells
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78 S57aGVHD enrolled in Blood and Marrow Transplant Clinical
Trials Network (BMT CTN) trials 0302 (N¼105, serum) and
0802 (N¼158, plasma). Samples were analyzed at aGVHD
onset and day 28 post-aGVHD treatment and compared to
control samples obtained at day +100 from University of
Minnesota allogeneic hematopoietic cell transplant (HCT)
recipients without aGVHD (N¼53, serum).
Results: In the pilot study, signiﬁcant differences in the levels
of FS, EGF, VEGF-A, PlGF, Ang2, and sEng were found when
comparing patients with aGVHD, allogeneic HCT recipients
without aGVHD, and HD in the pilot study. In the CTN vali-
dation cohorts (Figure 1), VEGF-A and EGF were signiﬁcantly
lower in patients with aGVHD compared to HCT controls. FS,
sEng, and PlGF were all signiﬁcantly elevated in patients
with aGVHD compared to controls. In multivariate analyses
of 6-month survival including age, stage, and day 28
response in the validation cohorts, the day 28 FS level was
an independent prognostic factor for survival in both CTN
0302 (HR 9.3, 95% CI 1.3e59.1, p¼0.002) and 0802 (HR 2.8,
95% CI 1.04e6.9, p¼0.04), with outcomes signiﬁcantly
worse when day 28 FS > 2000 pg/mL (Figure 2).Conclusions: Three circulating AFs are elevated in patients
with aGVHD: FS, sEng and PlGF. The level of FS at day 28 post
aGVHD was an independent prognostic factor for survival in
both CTN 0302 and 0802. Although FS is important for
regeneration after injury, excess FS may reﬂect more
extensive tissue, especially endothelial, damage or loss,
leading to higher mortality. Studies aimed at identifying the
source and mechanism of FS in aGVHD are ongoing. Our
results contribute to the growing body of knowledge
supporting the endothelium as a relevant target of aGVHD in
need of dedicated protection or therapy.41
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Using ﬂow cytometric techniques to directly analyze the
developing reactivity of T cells isolated from the recipient
after double cord blood transplant (dCBT) against cells
(B-LCL) derived from each donor, we previously reported
that naive CD8+ T cells in the engrafting unit are activated in
vivo by antigens expressed by non-engrafting unit, which
expand and differentiate into IFN-g secreting CD8+ effector T
cells. Surprisingly, our initial studies did not identify IFN-g
secreting alloreactive CD4+ T cells, despite the majority of CB
units being mismatched at one or more class II alleles
(Gutman et al. Blood 2010). However, these studies did
not exclude the possibility that CD4+ T cells, especially the
IFN-g- Th2 and Th17 cells, may be involved in the GvG
interactions of dCBT. Herein, we now demonstrate the
presence of alloreactive CD4+ T cells in dCBT recipients and
investigate their role in the GvG interaction. Included are 13
patients who underwent a myeloablative dCBT on an IRB
approved protocol between Feb 2013 and June 2014.
Post-transplant peripheral blood collection, donor B-LCL
generation, and in vitro MLR with intracellular cytokine
staining were performed as previously described (Gutman et
al. Blood 2010) with small revision. Our current experimental
approach includes the detection of surface marker CD137
